Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory TNBC
NCT04216472Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: terminated.
02
Drugs
alpelisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04216472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216472.